Please assess the completion status of the following clinical trial:

Trial Title: Topical Endoxifen in Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Participant in the Karma Cohort~* Attending the national mammography screening program, i.e., aged 40-74 and have performed a screening mammogram maximum 3 months prior to study inclusion~* Mammographic density \~4.5 % density (volumetric) measured by Volpara, at the screening mammogram performed in connection to baseline (maximum 3 months prior to inclusion). The threshold value of 4.5% corresponds to the clinical Bl-RADS score A~* Postmenopausal, defined as no period of menstruation during last 12 months independent of any hormonal treatment~* Informed consent must be signed before any study specific assessments are performed~Exclusion Criteria:~* Any previous or current diagnosis of breast cancer (including carcinoma in situ).~* Any previous diagnosis of cancer with the exception of non-melanoma skin cancer and in situ cancer of the cervix.~* A history of major surgery of the breast, e.g., reduction or enlargement, which might affect density measurements.~* Mammographic Bl-RADS malignancy code 3, or above, at baseline mammography, or at mammography during time of treatment. Recall for additional examinations due to technical problems with the mammogram is accepted.~* Currently using estrogen and progesterone based hormone replacement therapy (oral or patches). Local estrogen treatment is accepted (ex. Vagifem).~* Non-medical approved drugs against hot-flashes including phytoestrogen.

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: 74 Years
- Healthy Volunteers: t

Study Arms:
- Control (Type: PLACEBO_COMPARATOR): Topical Placebo:Transcutol™ (2-(2-Ethoxyethoxy)ethanol); isopropanol, Crodamol™ GTCC (a fully saturated emollient triester) and mineral oil
- Topical Endoxifen 10mg/breast/day (Type: ACTIVE_COMPARATOR): 10 mg/day topical (Z)-endoxifen; Transcutol™ (2-(2-Ethoxyethoxy)ethanol); isopropanol, Crodamol™ GTCC (a fully saturated emollient triester) and mineral oil
- Topical Endoxifen 20mg/breast/day (Type: ACTIVE_COMPARATOR): 20 mg/day topical (Z)-endoxifen; Transcutol™ (2-(2-Ethoxyethoxy)ethanol); isopropanol, Crodamol™ GTCC (a fully saturated emollient triester) and mineral oil

Based on this trial design, predict the completion outcome and termination type (if applicable).